Gland Pharma has announced impressive financial results for the year ended March 31, 2026. The company achieved a consolidated revenue of ₹64,307 million, marking a 14% increase year-on-year. Driven by strong performance across its base business and CDMO segment, the company also reported a 50% growth in adjusted profit after tax to ₹10,455 million. The board has recommended a final dividend of ₹20 per share for the fiscal year.
Financial Highlights for FY26
The company delivered a robust performance in the fourth quarter and full fiscal year 2026. Consolidated revenue for the full year climbed to ₹64,307 million, representing a 14% increase compared to the previous year. For the January-March 2026 quarter, revenue stood at ₹17,428 million, a 22% growth over the same period last year.
Profitability and Operational Growth
Profitability saw significant improvement, with adjusted consolidated PAT for the full year rising by 50% to ₹10,455 million. In the January-March 2026 quarter alone, adjusted PAT reached ₹3,667 million, reflecting a substantial 97% year-on-year increase. The adjusted EBITDA margin for the full year was recorded at 26%, supported by ongoing cost-efficiency initiatives and a strong product pipeline.
Key Business Developments
The company’s growth was fueled by its CDMO business, which contributed 46% to the total revenue for the year. Additionally, the base business showed strong market performance, with 31 new product launches in the USA during the fiscal year. Gland Pharma continues to expand its complex product pipeline, with a cumulative total of 388 ANDA filings in the U.S. market as of March 31, 2026.
Shareholder Returns and AGM
Reflecting the company’s strong financial health, the Board of Directors has recommended a final dividend of ₹20 per equity share for the fiscal year 2025-26. The 48th Annual General Meeting is scheduled for August 25, 2026, where the dividend payment will be subject to approval. The record date for determining member eligibility for the dividend is set for August 11, 2026.
Source: BSE
